MedPath

Radioactive Holmium Microspheres for the Treatment of Unresectable Liver Metastases

Phase 2
Completed
Conditions
Liver Neoplasms
Interventions
Device: Holmium-166 polylactic microspheres
Registration Number
NCT01612325
Lead Sponsor
UMC Utrecht
Brief Summary

Radioembolisation is a known method for the treatment of liver tumors and or livermetastases. Currently small beadlets called microspheres are used that are loaded with the beta radiation emitting Yttrium-90. Holmium-166 microspheres have different physical characteristics including good visualisation in gammacameras due to the gamma emission. Because of the higher specific activity higher radiation doses to the liver will be used compared to the standard Yttrium treatment. It is hypothesized that higher doses of irradiation have an improved antitumor effect.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Holmium-166 MS radioembolizationHolmium-166 polylactic microspheresSingle radioembolization met Holmium-166 polylactic microspheres administered
Primary Outcome Measures
NameTimeMethod
Target lesions tumour response3 month after treatment

After the administration of the Ho-166 microspheres the size of the target lesions in the liver will be determined using RECIST 1.1 criteria using CT scan

Secondary Outcome Measures
NameTimeMethod
Toxicity according CTC v 4 criteriaClinical evaluation after 1,3,6,9,12,24,36,52 weeks

Clinical evaluation and laboratory testing after week 1,3,6,9,12,24,36,52

Trial Locations

Locations (1)

Department of Radiology University Medical Center Utrecht

🇳🇱

Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath